MedTrace Logo

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

NCT07143864 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-27

No results posted yet for this study

Summary

This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.

Conditions

  • Primary Cutaneous Amyloidosis

Interventions

BIOLOGICAL

Stapokibart

A humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha

OTHER

Placebo drug

Placebo drugs without Stapokibart

Sponsors & Collaborators

  • First Affiliated Hospital of Chongqing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2026-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07143864 on ClinicalTrials.gov